tetano
Editor, Senior Moderator
Cancer Cell
. 2021 Jan 5;S1535-6108(21)00001-5.
doi: 10.1016/j.ccell.2021.01.001. Online ahead of print.
Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients
Sultan Abdul-Jawad[SUP] 1 [/SUP], Luca Ba?[SUP] 2 [/SUP], Thanussuyah Alaguthurai[SUP] 3 [/SUP], Irene Del Molino Del Barrio[SUP] 4 [/SUP], Adam G Laing[SUP] 5 [/SUP], Thomas S Hayday[SUP] 5 [/SUP], Leticia Monin[SUP] 6 [/SUP], Miguel Mu?oz-Ruiz[SUP] 6 [/SUP], Louisa McDonald[SUP] 7 [/SUP], Isaac Francos Quijorna[SUP] 8 [/SUP], Duncan McKenzie[SUP] 6 [/SUP], Richard Davis[SUP] 5 [/SUP], Anna Lorenc[SUP] 5 [/SUP], Julie Nuo En Chan[SUP] 1 [/SUP], Sarah Ryan[SUP] 9 [/SUP], Eva Bugallo-Blanco[SUP] 1 [/SUP], Rozalyn Yorke[SUP] 9 [/SUP], Shraddha Kamdar[SUP] 5 [/SUP], Matthew Fish[SUP] 10 [/SUP], Iva Zlatareva[SUP] 5 [/SUP], Pierre Vantourout[SUP] 5 [/SUP], Aislinn Jennings[SUP] 10 [/SUP], Sarah Gee[SUP] 5 [/SUP], Katie Doores[SUP] 11 [/SUP], Katharine Bailey[SUP] 12 [/SUP], Sophie Hazell[SUP] 12 [/SUP], Julien De Naurois[SUP] 13 [/SUP], Charlotte Moss[SUP] 14 [/SUP], Beth Russell[SUP] 14 [/SUP], Aadil A Khan[SUP] 15 [/SUP], Mark Rowley[SUP] 16 [/SUP], Reuben Benjamin[SUP] 17 [/SUP], Deborah Enting[SUP] 14 [/SUP], Doraid Alrifai[SUP] 13 [/SUP], Yin Wu[SUP] 18 [/SUP], You Zhou[SUP] 19 [/SUP], Paul Barber[SUP] 1 [/SUP], Tony Ng[SUP] 1 [/SUP], James Spicer[SUP] 1 [/SUP], Mieke Van Hemelrijck[SUP] 14 [/SUP], Mayur Kumar[SUP] 20 [/SUP], Jennifer Vidler[SUP] 21 [/SUP], Yadanar Lwin[SUP] 21 [/SUP], Paul Fields[SUP] 22 [/SUP], Sophia N Karagiannis[SUP] 23 [/SUP], Anthony C C Coolen[SUP] 24 [/SUP], Anne Rigg[SUP] 13 [/SUP], Sophie Papa[SUP] 25 [/SUP], Adrian C Hayday[SUP] 26 [/SUP], Piers E M Patten[SUP] 27 [/SUP], Sheeba Irshad[SUP] 28 [/SUP]
Affiliations
Abstract
Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19[SUP]+[/SUP] non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.
Keywords: COVID-19; SARS-CoV-2; antibodies; cancer; hemato-oncological; immune; seroconversion; vaccine; virus shedding.
. 2021 Jan 5;S1535-6108(21)00001-5.
doi: 10.1016/j.ccell.2021.01.001. Online ahead of print.
Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients
Sultan Abdul-Jawad[SUP] 1 [/SUP], Luca Ba?[SUP] 2 [/SUP], Thanussuyah Alaguthurai[SUP] 3 [/SUP], Irene Del Molino Del Barrio[SUP] 4 [/SUP], Adam G Laing[SUP] 5 [/SUP], Thomas S Hayday[SUP] 5 [/SUP], Leticia Monin[SUP] 6 [/SUP], Miguel Mu?oz-Ruiz[SUP] 6 [/SUP], Louisa McDonald[SUP] 7 [/SUP], Isaac Francos Quijorna[SUP] 8 [/SUP], Duncan McKenzie[SUP] 6 [/SUP], Richard Davis[SUP] 5 [/SUP], Anna Lorenc[SUP] 5 [/SUP], Julie Nuo En Chan[SUP] 1 [/SUP], Sarah Ryan[SUP] 9 [/SUP], Eva Bugallo-Blanco[SUP] 1 [/SUP], Rozalyn Yorke[SUP] 9 [/SUP], Shraddha Kamdar[SUP] 5 [/SUP], Matthew Fish[SUP] 10 [/SUP], Iva Zlatareva[SUP] 5 [/SUP], Pierre Vantourout[SUP] 5 [/SUP], Aislinn Jennings[SUP] 10 [/SUP], Sarah Gee[SUP] 5 [/SUP], Katie Doores[SUP] 11 [/SUP], Katharine Bailey[SUP] 12 [/SUP], Sophie Hazell[SUP] 12 [/SUP], Julien De Naurois[SUP] 13 [/SUP], Charlotte Moss[SUP] 14 [/SUP], Beth Russell[SUP] 14 [/SUP], Aadil A Khan[SUP] 15 [/SUP], Mark Rowley[SUP] 16 [/SUP], Reuben Benjamin[SUP] 17 [/SUP], Deborah Enting[SUP] 14 [/SUP], Doraid Alrifai[SUP] 13 [/SUP], Yin Wu[SUP] 18 [/SUP], You Zhou[SUP] 19 [/SUP], Paul Barber[SUP] 1 [/SUP], Tony Ng[SUP] 1 [/SUP], James Spicer[SUP] 1 [/SUP], Mieke Van Hemelrijck[SUP] 14 [/SUP], Mayur Kumar[SUP] 20 [/SUP], Jennifer Vidler[SUP] 21 [/SUP], Yadanar Lwin[SUP] 21 [/SUP], Paul Fields[SUP] 22 [/SUP], Sophia N Karagiannis[SUP] 23 [/SUP], Anthony C C Coolen[SUP] 24 [/SUP], Anne Rigg[SUP] 13 [/SUP], Sophie Papa[SUP] 25 [/SUP], Adrian C Hayday[SUP] 26 [/SUP], Piers E M Patten[SUP] 27 [/SUP], Sheeba Irshad[SUP] 28 [/SUP]
Affiliations
- PMID: 33476581
- DOI: 10.1016/j.ccell.2021.01.001
Abstract
Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19[SUP]+[/SUP] non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.
Keywords: COVID-19; SARS-CoV-2; antibodies; cancer; hemato-oncological; immune; seroconversion; vaccine; virus shedding.